Member Info for Trickymatters

Access to a market of 145 million people for faster regulatory approval of UK approved products and internationally recognised marketing. Ready to go January 2021.

MHRA approval could land anytime. I don't see any logic to the idea that the contract has to come first. I think the government's contracting is becoming the subject of litigation. I think they might be waiting for REACT 2 report on immunity. Can also drop anytime- these reports usually drop intraday. I think we could easily get more than one RNS a day once anything substantial drops.

Financial Times welcomes the government panel on testing. The rest of the story is implied in the headline. Good stuff.
Meanwhile the IMF has said today that environmental destruction makes us all vulnerable to one pandemic after another. In the short and medium term antibody and antigen testing used in conjunction and strategically can get us out of lockdowns with intelligence guiding properly managed, better targeted and supported, shorter quarantine. Then they will guide vaccine rollout. I can't see the US public giving a damn who makes the best tests in the world or the best vaccines. Johnson may have blotted our copy book with the Democrats with his puerile jokes but this is a global health emergency. We ain't China or Russia. Our standards are very rigorous. Mistakes with Abbott and Roche were early on. Their tests were the only ones widely available. Anyone would have run with them to be fair. All change now.

Thx for sharing Okehurst. Just seems to be pointing to us reaching the very cusp of MHRA approval. There has to be a plan to avoid another national lockdown. Government under relentless pressure to outline an exit plan for local lockdowns. I can see REACT 2 (biggest ever immunity study), self-assessment study and this final technical check being published this week one after another. Then MHRA approval.
Lead government scientists recognising 'new technologies ' about to come onstream in the press briefing today. Big climb just round the corner.
Then commercial orders next week and we will get to a new leg, 50% up is my guess.

Published today. Standards and scope for antibody testing. Says antibody testing will be rolled out across 4 nations of the UK starting with health workers and care workers to help us understand prevalence and increase our knowledge about the virus and immunity.

REACT1 prevalence study was published yesterday- on the 6pm news, radio4. So Imperial college said on October 1st it would be published 'next week ' ( yesterday October 9th) so they just made it. It also says REACT 2, the biggest immunity study to date is due 'very soon'. So I think that will be next week. It will show 3-4 months of immunity because every other study shows that and if you apply standard deviation properly it doesn't really matter how large the sample size is. Then we'll have the MHRA approval and government contract allowing for commercial sales in quick succession. Loving October for ODX.

Inspired find JAdam if you don't mind me saying so.

If the relationship is with Mologic, more likely to be for the Visitect Omega antigen and/or the Mologic antibody test. ODX also partnering on the latter with Mologic.

He's meant to be in a role evaluating tests. He's at Birmingham university who also have their own test. It's not as good as ours. Big conflict of interest.

Ask is showing the same as the sp on level 2. £1.07. Choo choo! I think it's time for me to do something else, lol.

Feel sorry for whoever it was that sold for 95p unless it's Sneller who has already done well. Bit concerned now for AVCT investors because they aren't going to have any solid news before Xmas and our news will be coming thick and fast for the rest of the month. 1 test in play and another 2 on the cusp! I can't help myself- choo choo! The train is leaving the station ;)

I'd like to see the Guardian apologise too. Very embarrassing for them. Normally a g8 paper but that is certainly a knock to their reputation. They should apologise unambiguously and think about the potential vested interests of business rivals in future. Poor show all round for Deeks and the Guardian imo. I pretty much never tweet but I did pick him up on it twice on Twitter. Only on it to see what's happening not to influence.

Brilliant interview. Sounds like £9.99 to government ('not even £10.00 per test to government '). 'Lateral flow tests are very competitive compared to other tests on the market now'. Bye bye Roche, Abbott et al. Lol.

Brilliant interview. Sounds like £9.99 to government ('not even £10.00 per test to government '). 'Lateral flow tests are very competitive compared to other tests on the market now'. Bye bye Roche, Abbott et al. Lol.

Government are giving away their tests for free. That's why we were originally assumed to get £1.50 each recognising government's investment in the context of a commitment for 200,000 a week. It's not in ODX interest to supply at that discounted price beyond the original agreement. Since then things have changed. Dido Harding and Jim Bethell have made it clear they assume a commercial domestic and international market (respectively). They won't be selling at a price offered to the government to pay back their investment, in domestic commercial and international markets. But I think they will be selling at fair and accessible prices. I think beyond the early mou we will be getting better margins. We'll soon see. Gla.

Mms are having a total laugh! Just seen a few 95p sells exchanged for a buy at £1.15 for £45k. You're better waiting for real volume on big news to get a fair price. Whatever though. Not my business. Trading every day is a mug's game imo.

Quite a lot of news due now. As I see it:
1. Contract. Either 7 million tests at 1.50 each fulfilling the early agreement though at a higher first order. Or 1 million tests at 10.00 each. More in line with, though still a discount from what government paid NCYT. Either way better than original assumptions for this first order. ODX will be supplying 25%. Implications for commercial sales come with the next element of the contract
2. Commercial sales for RTC. Retail prices £13-16.00 for pharmacies,and dentists. Professional distribution agencies already set up. So price for ODX to be advised but again, much higher than the government rate if that is £1.50. If it's £10.00 then guessing our cut could be £5-6.00. My assumption is based on the fact that ODX were assuming £5.00 for some of the Mologic tests. See first investor presentation. If government want them to dedicate resources to supply a good proportion of their capacity to this test they will have good negotiating power on the opportunity cost at anything lower.
Of course if the Mologic antigen poc test is part of the consideration then it is in ODX interest to ensure a very good level of capacity for this towards the Moonshot ambition for 3 million tests a day/week depending on which media outlet we believe if any. The Heathrow market is expected to be high volume and high value. Low levels of air passenger numbers are still in the millions daily outside of national lockdown periods. The point of tests for air passengers is to open up the industry again so, go figure.
Very exciting times! Gla. Oh by the way- another mate of mine asked for a tip for a £20k investment yesterday. Love her loads- ODX was my tip.

Our potential investment value has just shot up by nearly 550% for the UK government sales of the RTC. It will sell to the US for more- Jim Bethell has acknowledged the export potential of this product in the press release. So I guess we can start assuming a higher baseline for revenues across all our tests? And whatever those new prices X 10 million a week from January. Cooking with gas people!

Not necessarily on the list of exceptional use items. Just keep an eye on the daily MHRA releases and the PHE site.

DNA Nudge were taken off the exceptional exemption list on the MHRA list this week I noticed.